SLN Silence Therapeutics plc

Nasdaq silence-therapeutics.com


$ 6.48 $ -0.67 (-9.34 %)    

Monday, 03-Nov-2025 11:20:17 EST
QQQ $ 631.65 $ -3.57 (-0.56 %)
DIA $ 473.69 $ -2.56 (-0.54 %)
SPY $ 682.56 $ -3.07 (-0.45 %)
TLT $ 89.48 $ -0.17 (-0.19 %)
GLD $ 368.33 $ -0.47 (-0.13 %)
$ 7.16
$ 7.17
$ 6.40 x 510
$ 6.52 x 6
$ 6.42 - $ 7.01
$ 1.97 - $ 18.29
93,933
na
338.2M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silence-therapeutics-completes-patient-enrollment-in-phase-2-study-of-divesiran

Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $7...

 chardan-capital-maintains-buy-on-silence-therapeutics-maintains-35-price-target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $35 price target.

 correction-silence-therapeutics-q2-eps-057-misses-023-estimate-sales-224000k-miss-5430m-estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 chardan-capital-maintains-buy-on-silence-therapeutics-maintains-35-price-target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $35 price target.

 silence-therapeutics-presents-additional-data-showcasing-sanreco-phase-1-study-of-divesiran-in-patients-with-pv-at-eha-2025-annual-meeting

Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Div...

 goldman-sachs-maintains-sell-on-silence-therapeutics-lowers-price-target-to-3

Goldman Sachs analyst Richard Law maintains Silence Therapeutics (NASDAQ:SLN) with a Sell and lowers the price target from ...

 morgan-stanley-maintains-overweight-on-silence-therapeutics-lowers-price-target-to-25

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and lowers the price target...

 chardan-capital-maintains-buy-on-silence-therapeutics-lowers-price-target-to-35

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and lowers the price target from $...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 morgan-stanley-maintains-overweight-on-silence-therapeutics-lowers-price-target-to-45

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and lowers the price target...

 bmo-capital-maintains-outperform-on-silence-therapeutics-lowers-price-target-to-25

BMO Capital analyst Kostas Biliouris maintains Silence Therapeutics (NASDAQ:SLN) with a Outperform and lowers the price targ...

 goldman-sachs-maintains-sell-on-silence-therapeutics-lowers-price-target-to-4

Goldman Sachs analyst Richard Law maintains Silence Therapeutics (NASDAQ:SLN) with a Sell and lowers the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION